Publication details
Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE |
| MU Faculty or unit | |
| Citation | |
| Web | http://dx.doi.org/10.1016/j.jaip.2019.05.042 |
| Doi | http://dx.doi.org/10.1016/j.jaip.2019.05.042 |
| Keywords | C1-INHIBITOR CONCENTRATE |
| Description | Hereditary angioedema (HAE) is a rare (<1 in 50,000) ge-netic disorder characterized by episodes of cutaneous andmucosal angioedema. HAE is caused by insufficient suppressionof complement and contact-system cascades due to a deficiencyof functional C1 inhibitor (C1-INH). It has been demonstratedthat HAE abdominal attacks are more frequent during preg-nancy, but there is no consensus on which trimester is mostassociated with increased attack rates.Some data suggest thatmore severe attacks and symptoms occur during thefirsttrimester, whereas other data suggest a greater number of attacksin the second and third trimesters. Changes in hormone levelsduring pregnancy may exacerbate HAE attacks, and concernswith administration of certain medications during pregnancy cancomplicate HAE management. |